Market Size & Trends
The Europe biotechnology and pharmaceutical services outsourcing market size was estimated at USD 10.0 billion in 2023 and is expected to grow at a CAGR of 5.75% from 2024 to 2030. Some of the key factors driving the growth of this market include the substantial increase in inclination towards outsourcing R&D activities to expert organizations, changing regulatory landscape, rising focus of biotechnology and pharmaceutical on core competencies, high clinical development failure rates, and increasing drug development costs.
Europe biotechnology and pharmaceutical services outsourcing market held a share of 21.7% of the global biotechnology and pharmaceutical services outsourcing market revenue in 2023. Several industry dynamics are encouraging biotechnology and pharmaceutical companies to outsource functions, such as clinical development, quality management, regulatory writing & publishing, product registration & clinical trial applications, research, strategy, & concept generation design verification & validation, auditing, product maintenance, training, and more.
Well-established regulatory outsourcing firms, contract research organizations (CROs), management consulting firms, and manufacturers working on contracts are diligently taking care of the complex demands of the pharmaceutical and biotechnological sectors.
End-use Insights
Based on the end-use, the pharmaceutical companies segment held the largest share of 57.6% in 2023. This segment is primarily driven by factors, such as the need for assistance developed due to the changing nature of regulatory scenarios, enhanced product design & development accomplished through outsourcing, and improved product testing & validation attained through expert assistance.
An increase in expenditure on R&D by pharmaceutical companies for the discovery and development of potential unique products is anticipated to drive market growth in the coming years. The biotech companies segment is expected to reregister a CAGR of 6.11% from 2024 to 2030.
Service Insights
The consulting services segment dominated the regional market and held a revenue share of 24.4% in 2023. Consulting businesses provide various services to assist companies in meeting regulatory compliances as well as quality standards and reducing environmental damages. For a pharmaceutical company, these businesses offer an enhanced level of expertise and experience. A rise in fraudulent cases and constant growth in technological innovations are two of the major challenges encountered by pharmaceutical/biotechnological companies. Therefore, such companies are inclined towards outsourcing a few functions.
The training & education segment is expected to register a CAGR of 4.31% from 2024 to 2030. This is mainly due to the ever-changing nature of the industry. Technological enhancements, changes in business functions, and fluctuations in political & economic scenarios make this industry extremely dynamic. This creates challenges for employees and professionals in keeping up with the required know-how and skills. The training and education services provided by expert organizations assist them in keeping themselves updated and equipped with the necessary competencies.
Country Insights
Germany Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The Germany biotechnology and pharmaceutical services outsourcing market dominated the regional industry and accounted for a share of 25.2% in 2023. Germany is one of the largest pharmaceutical markets in the world after the U.S., Japan, and France, which is one of the major factors responsible for the high demand for pharmaceutical and biotechnology contract services in the country.
France Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The biotechnology and pharmaceutical services outsourcing market in France is expected to register a CAGR of 6.2% from 2024 to 2030. Smaller pharmaceutical and biotechnology companies in France are increasingly entering the market by offering generics at lower prices and shifting the focus of major players in the healthcare industry toward innovation by developing novel drugs.
Key Europe Biotechnology And Pharmaceutical Services Outsourcing Company Insights
Some of the key and emerging companies in the Europe biotechnology and pharmaceutical services outsourcing market include Concept Heidelberg GmbH, ICON plc, Venus Pharma GmbH, Kindeva Drug Delivery, Midas Pharma GmbH, IQVIA Inc., and others. The highly competitive market encourages companies to embrace advanced technologies, accommodate changes in manufacturing processes, and develop highly skilled and competitive teams of experts.
Concept Heidelberg GmbH offers consulting, as well as training & education, services to multiple organizations. The company delivers approximately 350 conferences and seminars in nearly 10 countries. These seminars are related to areas, such as Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), GDP certifications, GMP certifications, and more
Venus Pharma GmbH provides services, such as licensing, contract manufacturing, product development, product testing & release, packaging, warehouse & logistics, and research
Key Europe Biotechnology And Pharmaceutical Services Outsourcing Companies:
- Concept Heidelberg GmbH
- ICON PLC
- Venus Pharma GmbH
- Kindeva Drug Delivery
- Midas Pharma GmbH
- IQVIA Inc.
Recent Developments
In January 2024, Kindeva Drug Delivery, one of the leading organizations in drug-device combination products, acquired Summit Biosciences Inc., a renowned drug-delivery contract development and manufacturing organization (CDMO)